Breast Cancer Trials

Breast Cancer Trials is committed to exploring and finding better treatments for people affected by breast cancer through clinical trials research. We are a group of world-leading breast cancer researchers based in Australia and New Zealand, supported by a team of professional staff who manage our clinical trials and raise the money we need to do the work we do. Our research has improved the treatment of breast cancer, led to changes in the way breast cancer is managed, and saved the lives of millions of people affected by breast cancer since our inception in 1978. Our goal is for breast cancer patients to live better, to live longer, and to never die from breast cancer. The work we do and the decisions we make serve the common good of all people who are affected with breast cancer, as we strive every day to make the world a better place. Organisations don’t make things happen; people do. Are you one of these people? Find out more: https://lnkd.in/g3ZtRBP9

Curious about the role and impact of diet and exercise in breast cancer care? Why not register for our free and online Q&A being held on Thursday 14 November from 5-6:30pm (AEDT). For more information visit: https://lnkd.in/g6fMmRQ2

The OLIO clinical trial aims to find out if the addition of olaparib, or a combination of olaparib and durvalumab, given together with standard chemotherapy, can help to control cancer in pre-menopausal women with HR-positive, HER2-negative breast cancer. Young patients with HR-positive, HER2-negative breast cancer are often treated with hormone therapy and chemotherapy and have a 2-3x increased risk of breast cancer recurrence over their lifetime. It is believed that targeted treatments in addition to chemotherapy could improve patient outcomes for young, early breast cancer patients. Through a combination of these treatments, we hope that this will deliver an improved approach to the treatment of breast cancer in young women who have a high risk of relapse and will improve patient outcomes. Find out more: https://lnkd.in/gvrbHYT3

MEET OUR EXPERT PANEL Join us for our next free and online Q&A discussing the role and impact of diet and exercise in breast cancer care. Moderated by Author and Journalist, Annabel Crabb, we’ve lined up a panel of experts to answer your questions about this important topic, including: Ms Melissa Bell: Diagnosed with Stage 3 ER+ PR+ HER2+ breast cancer in 2013, at the age of 40. She has been a member of the Consumer Advisory Panel at Breast Cancer Trials for the last eight years. She was a participant in the Expinkt (Exercise training beyond breast cancer) programme at Otago University. Dr Di Adams: Experienced medical oncologist who has worked as a Senior Staff Specialist in Medical Oncology at the Macarthur Cancer Therapy Centre for 23 years. Professor Marina Reeves: Professor in the School of Public Health and Deputy Associate Dean of Research (Researcher Development) in the Faculty of Medicine. She is also an Advanced Accredited Practising Dietitian and in 2021 was awarded the Dietitians Australia Barbara Chester Award for her leadership in dietetics in Queensland. Dr Eva Zopf: Exercise physiologist whose research interest focuses on the role of exercise as medicine for the management of cancer. Register now for this free event on Thursday 14 November from 5-6:30pm (AEDT). https://lnkd.in/g6fMmRQ2

We want better outcomes for patients today and in the future, and we won't stop until no more lives are cut short by breast cancer. Find out more about how you can help: https://lnkd.in/gG9_YiXf

The OPTIMA clinical trial aims to find out if using a test called Prosigna, can help make safe and accurate decisions about whether or not chemotherapy treatment is needed for patients with ER-positive, HER2-negative early breast cancer. "We know that we often are giving chemotherapy to women who don't get a benefit from it, so OPTIMA is trying to see if a test on someone's breast cancer tumour can work out whether they might be able to do just as well without having to receive chemotherapy." - OPTIMA Study Chair, Belinda Kiely For more information about this important research visit: https://lnkd.in/gmzfq5mt

Join us for our next free and online Q&A, moderated by Author and Journalist Annabel Crabb, as our panel of experts discuss the role and impact of diet and exercise in breast cancer care. For breast cancer patients, maintaining a balanced diet and regular exercise is crucial for managing health and improving outcomes. Diet and exercise also intersect in the management of treatment side effects. For instance, hormonal therapies used in breast cancer treatment can affect bone density and increase the risk of osteoporosis. A diet rich in calcium and vitamin D, along with weight-bearing exercises, can help mitigate this risk. Join us for our next insightful and empowering Q&A on Thursday 14 November from 5-6:30pm (AEDT). This session will explore how diet and exercise can significantly enhance the quality of life for breast cancer patients and survivors. For more information or to register visit: https://lnkd.in/g6fMmRQ2

This week marks the end of Breast Cancer Awareness Month... Today, we're sharing some of the inspiring messages of support we've received this month through our "NO MORE" campaign to stop breast cancer taking the people we love. 🩷 To leave your own message of support on our Solidarity Wall, click here: https://bit.ly/4e3qZnc Donate now and join us to see a world where NO MORE lives are cut short by breast cancer! Let's stand together to support these women and save lives today, tomorrow and forever.

In one of our latest podcast episodes, Dr Anna Singleton discusses the EMPOWER-SMS clinical trial and what it aims to achieve for breast cancer patients. Dr Anna Singleton is a Senior Research Fellow at the Daffodil Centre, a joint venture between the University of Sydney and Cancer Council NSW. Her research focuses on co-designing and implementing accessible and scalable digital health services to improve health outcomes for people living with and beyond cancer. Find out more: https://lnkd.in/gjskdEx8

Breast Cancer Trials Annual Scientific Meeting (ASM) brings together eminent international researchers, guest speakers, and big thinkers, to showcase the best ideas and updates on breast cancer clinical trials research. During our 45th ASM in Cairns, we had the pleasure of interviewing Professor Carlos Barrios, who is the Co-Founder and Director of the Latin American Cooperative Oncology Group, as well as Director of Clinical Research and Oncologist of the Oncoclicas Group in Porto Alegre, Brazil. We spoke to him about the 'sequencing of antibody-drug conjugates' and 'what to do after metastatic breast cancer patients progress on CDK4/6i'. Find out more: https://lnkd.in/g7FDJ-3K